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OBJECTIVES: A large retail employer implemented Mercer’s Dx-Rx PairingTM 
program. This program offers reduced copayments on diabetes, coronary artery 
disease, heart failure, and asthma medications with concurrent enrollment in disease 
management. We measured adherence and assessed medical utilization in 771 program 
enrollees (intervention group) and in those eligible but not enrolled (control group, 
n  997). METHODS: Adherence, deﬁned by Proportion of Days Covered (PDC), 
was calculated using incurred prescription drug claims one year before and 6 months 
after implementation of Dx-RxTM. Paired t-test analysis compared the change in adher-
ence pre- vs. post-implementation in both intervention and control groups. We calcu-
lated propensity scores to adjust for selection bias and subsequently used regression 
analysis to compare the change in adherence between groups. RESULTS: The overall 
adherence in the intervention group increased by 7% (p  0.001) after implementation 
of Dx-RxTM, whereas the overall adherence in the controls decreased by 9% (p  
0.001). Adherence improved especially for inhaled steroid use among Dx-RxTM asth-
matics (46%, p  0.011). However, adherence among diabetics to angiotensin-convert-
ing enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) did not 
improve in either the intervention or the control group (2%, p  0.509; 8%, p  
0.002, respectively). Regression analysis concurred that Dx-RxTM enrollees had a 
greater improvement in PDC than the controls (B  0.094, p  0.001). Larger increases 
in both prescription and medical per member per month (PMPM) costs were also seen 
in Dx-RxTM enrollees. CONCLUSIONS: The Dx-RxTM program improved adherence, 
but did not reduce medical costs in this timeframe. Subanalyses revealed areas of the 
program’s success and areas for improvement.
PHP26
IMPOVERISHING MEDICINES: A CROSS-COUNTRY COMPARISON OF 
THE AFFORDABILITY OF MEDICINES
Niëns LM
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OBJECTIVES: In low- and middle-income countries medicine costs account for a 
substantial part of total health care costs (WHO estimate: 25–70%). In these countries 
many patients pay for medicines out-of-pocket. This study’s aim was to calculate the 
affordability of four essential medicines (salbutamol inhaler (100 mcg/dose), gliben-
clamide (5 mg), atenolol (50 mg) and amoxicillin (250 mg)) for 17 low- and middle-
income countries. METHODS: Previous research expressed affordability of medicines 
in the number of days’ wages of the lowest paid unskilled government worker. Using 
medicine prices from a joint project between Health Action International & WHO, 
and expenditure data and income distributions from the World Bank, this study 
applied a more common measure of affordability of medicines based on impoverish-
ment (i.e., percentage below US$1 or $2 per day after medicine procurement). Afford-
ability is calculated for Originator Brand (OB) and Lowest Priced Generic (LPG) 
medicines in both the public and private sector. RESULTS: OB medicines are less 
affordable than LPG medicines. Impoverishment rates (IRs) between OB and LPG 
medicines vary substantially; 10.8% vs. 4.0% (OB vs. LPG below US$1, public sector 
atenolol, Philippines). IRs of up to 33.6% were found (below US$1, OB private sector 
amoxicillin, Indonesia). IRs in low-income countries are lower than in middle-income 
countries due to high numbers already living below US$1 or $2 per day. We distin-
guish between those being impoverished and those for whom medicines are unafford-
able in the ﬁrst place (i.e. below US$1 or $2 before medicine procurement). In the 
public sector IRs are lower than in the private sector but availability of medicines is 
low. CONCLUSIONS: In low- and middle-income countries medicine prices in rela-
tion to available income are such that obtaining necessary medication will impoverish 
large numbers of people. These results call for action by politicians, policymakers, and 
civil societies.
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ASSESSMENT OF THE INTERNATIONAL NONPROPRIETARY NAMES 
(INN) PRESCRIBING PILOT PROJECT IN SOUTH KOREA
Kim JY, Lee EK
Sook Myung Women’s University, Seoul, South Korea
OBJECTIVES: The pilot project of International Nonproprietary Names (INN) was 
implemented over nine months at the National Medical Center (NMC). This study 
aimed to assess the impact of INN on its prescribing rate and drug cost savings. 
METHODS: National health insurance claims data were used to analyze the extent 
to which INN prescribing was conducted for outpatients at NMC, and to know which 
drugs were dispensed at pharmacies. INN prescribing rates were compared by month, 
type of clinics, patient’s characteristics and drug classiﬁcations. Also, drug cost savings 
were compared with brand name in terms of average cost, the rate of the highest-priced 
drug, and total drug expenditure. RESULTS: INN prescribing rate was 31.76%. The 
rate was higher for non-prescription drugs (30.2%) than for prescription drugs 
(15.92%). The rate increased with the age of patient; it was higher for patients with 
health insurance (33.61%) than those on Medicaid (26.75%); the rate was higher for 
re-visit (33.7%) than the ﬁrst visit (9.94%). Specialties with the highest rate were 
Internal Medicine and Neurology. Average cost of INN prescribing was lower than 
the brand name prescribing before and during pilot project. Total drug expenditure 
was reduced by 3.63% compared to before the pilot project, and by 4.58% compared 
to brand name prescription during pilot project. CONCLUSIONS: In conclusion, 
doctors’ INN prescribing rate was 31.76% and drug cost savings compared to brand 
name prescription was 3.63% and 4.58% respectively, for before and during pilot 
project. To achieve better results, active participation of doctors in INN prescribing 
and dispensing low-priced drug by pharmacists are essential.
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OBJECTIVES: Pharmaceutical care perception study. METHODS: Survey. RESULTS: 
Patients expectations. CONCLUSIONS: Poland is one of the last countries in the 
European Union in terms of the advancement of the system of pharmaceutical care.       
Polish Pharmaceutical Council accepted a programme called the Strategy of the Phar-
maceutical Care in Poland over two years ago. Introducing the pharmaceutical care 
is not obligatory, but more and more frequently it is perceived as an element of the 
long-term strategy of pharmacies development. The survey was conducted in 2009. 
Apart from identiﬁcation of social expectations concerning pharmaceutical care, the 
survey aimed at determining to what extent is the society informed about this process. 
The survey was conducted in a group of 848 responders. In 65% of the cases, the 
patients did not encounter the pharmaceutical care programme and were not informed 
that it is being implemented by the Polish Health Service, 73% of responders were 
interested in taking part in the care process, expecting some beneﬁts. The responders 
expect the following beneﬁts: 29%—ﬁnancial savings, 28%—avoiding drug inter-    
actions, 24%—reduction of quantity of taken preparations, 14%—control to take         
medicines appropriately, 5%—motivation to dose the medicines appropriately The       
biggest problem for the responders was making notes on utilization of medicines in a 
diary (59%). The other expected problems are: informing the pharmacist about the  
course of pharmacotherapy (24%) and the necessity to follow new rules and being 
systematic (17%). The conducted survey shows that patients are interested in taking 
part in the care process and in result they expect notable ﬁnancial beneﬁts and reduc-
tion of the quantity of medicines taken. To implement efﬁciently the care in pharmacies 
and to encourage patients to take part in the programme, it is necessary to prepare a 
message aimed at fulﬁlment of actual expectations and social needs.
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UN POUR TOUT, TOUT POUR UN? AN EMPIRICAL ANALYSIS OF 
PHARMACEUTICAL COVERAGE DECISIONS IN THREE COUNTRIES
Harris A
Monash University, Clayton, VIC, Australia
OBJECTIVES: National public insurance coverage of drugs is based on evidence of 
comparative effectiveness and cost effectiveness. This study compares the importance 
of these issues across three jurisdictions (Australia, Canada, England and Wales) that 
have been at the forefront of evidence-based coverage internationally. METHODS: 
A retrospective comparative analysis of data on factors that have been inﬂuential in 
pharmaceutical public insurance coverage decision in England and Wales (NICE), 
Australia (PBAC) and Canada (CDR) was conducted. The probability of coverage for 
drugs was compared across jurisdictions by each key factor. Data items on all drugs 
considered for 2004 to 2008 were extracted from publicly available documents on 
coverage decisions in each country. RESULTS: Recommendations varied considerably 
across countries in part because of different processes including the willingness to 
negotiate on price and the associated attitude to market proliferation of drugs with 
similar characteristics. The data suggest that the three agencies make recommendations 
that are consistent with a cost effectiveness framework; although it is clear that these 
committees have other objectives in addition to efﬁciency. This is consistent with 
previous empirical studies that suggest the strength of evidence of the comparative 
effectiveness of the drug as well the budgetary cost to government is also signiﬁcant 
predictors of listing in addition to cost-effectiveness. CONCLUSIONS: NICE, PBAC, 
and CDR continue to face common issues with respect to the quality and strength of 
the experimental evidence in support of a clinically meaningful effect. There are sig-
niﬁcant differences in recommendations across countries in part due to differences in 
interpretation of evidence differences in objectives and associated processes, particu-
larly with respect to price negotiation.
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A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK
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OBJECTIVES: 1) Compare the quality of primary care in France to that in the UK 
through a comparison of the avoidable hospitalization rates in both countries, and 2)          
Shed light on the determinants of the quality of primary care through a comparison 
of practices between the two countries for three Avoidable Hospital Conditions 
(AHC). METHODS: We counted the total number of hospitalizations for 12 AHCs 
deﬁned by Weissman et al. Patient hospitalization records were drawn from the PMSI 
database for France (2006) and the HES database for England (April 2006–May 
